임상시험 이미징 시장 규모, 점유율, 동향 분석 보고서 : 모달리티별, 치료 분야별, 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Clinical Trial Imaging Market Growth & Trends:

The global clinical trial imaging market size is expected to reach USD 1.91 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth. Images obtained from the internal examination of the body are used to determine drug activity. Clinical trial imaging provides rapid, detailed, and accurate screening. The need for clinical trial imaging is rapidly increasing in all phases of trials. Medical imaging in clinical trials is used as a primary, quantitative, and surrogate biomarker.

The clinical trial design includes selecting patient population, stratification based on biomarkers, different methods for allocation treatments, choosing efficient and reliable endpoints and validation of surrogate endpoints, calculating sample size, trial simulations, adaptive trial set-up, statistical and interim analysis, and assisting clients to deal with regulatory authorities such as EMA and FDA to discuss study design or defend study results.

Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development. IXICO offers advanced technologies for catalyzing clinical trials in neuroscience. Imaging biomarkers by the company help in measuring the safety and effectiveness of therapies used for neuro-imaging. Imaging biomarkers are effective in radiological reads. This provides the reading of MRI scans for central neuro to enhance the assessment of ongoing monitoring of drug safety and subject eligibility

Clinical Trial Imaging Market Report Highlights:

• The reading and analytical services segment held the largest market share at 30.95% in 2024 and is expected to grow at a CAGR of 8.4% from 2025 to 2030, highlighting its critical role in ensuring the accuracy and reliability of imaging data in clinical research.
• The biotechnology and pharmaceutical companies segment accounted for the largest share of 28.7% in 2024. The factor attributing to the dominance of this segment is the need to develop new drugs and therapies to cure chronic diseases.
• Oncology segment held the largest market share of 23.63% in 2024. High prevalence of cancer cases and the constant need for new and innovative therapies to treat various types of cancer are expected to fuel the market growth.
• The contract research organizations (CROs) segment is expected to grow significantly with a CAGR of 8.5% over the forecast period, owing to its essential role in developing new drugs and therapies for chronic diseases.
• North America dominated the market with a revenue share of 47.93% in 2024 due to the increasing geriatric population, along with chronic diseases and growing demand for treatment options.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Modality
  • 1.2.2. Therapeutic Area
  • 1.2.3. Services
  • 1.2.4. End Use
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Modality outlook
  • 2.2.2. Therapeutic area outlook
  • 2.2.3. Services outlook
  • 2.2.4. End Use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Clinical Trial Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing number of pharmaceutical and biotechnological companies
    • 3.2.1.2. Growing number of contract research organization (CRO)
    • 3.2.1.3. Increasing research and development investments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of machineries and installations
• 3.3. Clinical Trial Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Clinical Trial Imaging Market: Modality Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Clinical Trial Imaging Market: Modality Movement Analysis
• 4.3. Clinical Trial Imaging Market by Modality Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Computed Tomography Scan
  • 4.5.1. Computed Tomography Scan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Magnetic Resonance Imaging
  • 4.6.1. Magnetic Resonance Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. X-Ray
  • 4.7.1. X-Ray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Ultrasound
  • 4.8.1. Ultrasound Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Optical Coherence Tomography (OCT)
  • 4.9.1. Optical Coherence Tomography (OCT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Other Modalities
  • 4.10.1. Other Modalities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Clinical Trial Imaging Market: Therapeutic Area Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Clinical Trial Imaging Market: Therapeutic Area Movement Analysis
• 5.3. Clinical Trial Imaging Market by Therapeutic Area Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Neurovascular Diseases
  • 5.5.1. Neurovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cardiovascular Diseases
  • 5.6.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Orthopedics & MSK Disorders
  • 5.7.1. Orthopedics & MSK Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Oncology
  • 5.8.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Ophthalmology
  • 5.9.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Nephrology
  • 5.10.1. Nephrology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Other Therapeutic Areas
  • 5.11.1. Other Therapeutic Areas Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Clinical Trial Imaging Market: Services Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Clinical Trial Imaging Market: Services Movement Analysis
• 6.3. Clinical Trial Imaging Market by Services Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Clinical Trial Design and Consultation Services
  • 6.5.1. Clinical Trial Design and Consultation Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Reading and Analytical Services
  • 6.6.1. Reading and Analytical Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Operational Imaging Services
  • 6.7.1. Operational Imaging Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. System and Technology Support Services
  • 6.8.1. System and Technology Support Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Project and Data Management
  • 6.9.1. Project and Data Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Clinical Trial Imaging Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Clinical Trial Imaging Market: End Use Movement Analysis
• 7.3. Clinical Trial Imaging Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Biotechnology and Pharmaceutical Companies
  • 7.5.1. Biotechnology and Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Medical Devices Manufacturers
  • 7.6.1. Medical Devices Manufacturers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Academic and Government Research Institutes
  • 7.7.1. Academic and Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Contract Research Organizations (CROs)
  • 7.8.1. Contract Research Organizations (CROs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Other End Users
  • 7.9.1. Other End Users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Clinical Trial Imaging Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.8.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.8. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. Middle East & Africa
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.1.1 Company/Competition Categorization
  • 9.1.2. Innovators
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2024
  • 9.2.4. IXICO plc
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Navitas Life Sciences
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Resonance Health
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. ProScan Imaging
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Radiant Sage LLC
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Medpace
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Biomedical Systems Corp.
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Cardiovascular Imaging Technologies
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Intrinsic Imaging
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Product benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. BioTelemetry
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Product benchmarking
    • 9.2.13.4. Strategic initiatives